7-Hydroxymitragynine: minority alkaloid with outsized effects

Scope and caveats

This page summarises the peer-reviewed pharmacology of 7-hydroxymitragynine (7-OH) and surfaces the regulatory distinction between 7-OH as it occurs naturally in Mitragyna speciosa leaf and the concentrated or synthetic 7-OH products that have appeared in commerce. Each scientific claim links to a primary source.

kratom.com's product scope on this site is whole leaf and full-spectrum extracts. The discussion of concentrated and synthetic 7-OH below is included because it is the most consequential regulatory question in the category — not because the products are part of this catalogue.

Where 7-OH appears in the plant

7-OH is a minor alkaloid in Mitragyna speciosa leaf. Reported concentrations in dried leaf material are typically in the range of 0.01–0.05% by weight — roughly one to two orders of magnitude lower than the dominant alkaloid mitragynine, which sits at approximately 1–2% by weight in well-handled leaf.^[2,4]

Quantification at these low concentrations requires sensitive analytical methods. The UPLC-MS/MS approach reported by Sharma et al. (2019) is one of the validated reference methodologies for parallel quantification of 7-OH alongside mitragynine and other indole alkaloids in raw leaf and commercial products.^[4]

Receptor pharmacology

7-OH binds to the μ-opioid receptor with substantially higher affinity than mitragynine. Kruegel et al. (2016) reported the foundational receptor-signalling characterisation; the authors concluded that mitragynine itself has weak μ-opioid receptor affinity, and that the opioid-like effects observed in animal models are largely driven by 7-OH — both 7-OH preformed in the leaf and 7-OH generated through metabolism of mitragynine.^[1]

Obeng et al. (2020) extended this work with a broader functional and binding-affinity characterisation of multiple indole-based kratom alkaloids, confirming the mitragynine / 7-OH potency ratio at the μ-opioid receptor and describing their differential profiles at adrenergic and other opioid receptors.^[2]

7-OH acts as a partial μ-opioid agonist rather than a full agonist. Henningfield et al. (2022) reported that, in a controlled rodent model, oral mitragynine produced no significant respiratory depression even at exposures well above typical human dose ranges, while oxycodone (a full μ-opioid agonist) at lower relative doses produced dose-related respiratory depression and lethality. The authors attribute the contrast to the partial-agonist profile characteristic of mitragynine and 7-OH from natural-leaf material.^[3]

Natural-leaf 7-OH vs concentrated and synthetic 7-OH

The pharmacological discussion above is grounded in studies of natural-leaf material — kratom in which 7-OH is present at its naturally-occurring trace concentration alongside mitragynine and the other ~40 alkaloids in the leaf.

Products in which 7-OH is concentrated, isolated, or synthesised separately are a distinct category. The receptor binding profile of 7-OH does not change with concentration, but the dose presented to a user from a 7-OH-enriched product is materially different from the dose of 7-OH in a serving of whole leaf — by orders of magnitude in some commercial products. The pharmacological evidence summarised above should not be assumed to generalise from natural-leaf exposure to concentrated 7-OH exposure.

The U.S. Food and Drug Administration has communicated separately on this distinction; their public-health focus page on 7-OH products specifically addresses concentrated and synthetic forms rather than whole leaf.^[5]

Regulatory framing

Most state-level Kratom Consumer Protection Act (KCPA)-modelled statutes treat 7-OH concentration as a distinct provision — typically capping 7-OH content as a percentage of total alkaloids or per serving, with the cap value the most variable element across enacted versions. The regulatory question is the cap, not the presence of 7-OH; natural-leaf concentrations sit comfortably below commonly-adopted caps.

For the per-state KCPA detail, see the KCPA model legislation brief in Resources / Policy.

Open questions

• ·The contribution of preformed 7-OH versus metabolically-generated 7-OH to systemic 7-OH exposure after oral kratom consumption.
• ·The dose-response curve for partial-agonist effects at the μ-opioid receptor as 7-OH concentration scales — i.e. whether the partial-agonist character holds at the concentrations seen in concentrated 7-OH products, or whether dose-related respiratory depression emerges.
• ·Long-term safety data for natural-leaf 7-OH exposure from extended kratom use is still developing. Smith, Garcia-Romeu, and colleagues have published observational and ecological-momentary-assessment work that is informative but not the same as controlled long-term clinical study.